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Multiple myeloma represents 1% of all cancers and 15% of hematologic malignancies (1). Despite 
improvements in outcomes for this disease over the past several decades, the 5-year survival rate is still 
only 50%.  
Kidney dysfunction is common in myeloma, and it is present in 40% of patients at diagnosis; close to 
15% of patients require dialysis at the time of presentation (2). The most common etiology is AKI from 
cast nephropathy. Patients with cast nephropathy have poorer 1-year survival compared with patients 
without kidney involvement. This poor prognosis is reversible if kidney function is restored (3). The 
primary mechanism of kidney injury is coprecipitation of filtered free light chains with Tamm–Horsfall 
protein in the distal tubules.  
With melphalan- and cyclophosphamide-based chemotherapy used in the past, reduction of serum free 
light-chain concentrations was gradual, and kidney recovery and dialysis independence were infrequent. 
With the advent of newer therapeutic agents, particularly the proteasome inhibitor bortezomib, the 
reduction of serum free light-chain concentrations is more rapid, and kidney recovery is significantly 
improved. However, the overall rate of hemodialysis independence remains poor, with response rates of 
30% in most series.  
Recognition that rapid reduction in the concentration of free light chains is associated with improved 
kidney outcomes in patients with cast nephropathy has led to a renewed interest in extracorporeal 
methods of free light-chain removal (4). 
The application of extracorporeal therapy for cast nephropathy initially began with the use of 
plasmapheresis as a means of free light-chain removal. Although several trials reported improved kidney 
recovery, the data were severely flawed. The largest randomized, controlled trial of plasmapheresis for 
treatment of presumed cast nephropathy was reported over a decade ago (5). This study randomized 
104 patients to either standard medical care (pre-bortezomib era) or five to seven plasmapheresis 
sessions in addition to standard of care. There was no difference between the two groups in the 
composite end point of death, dialysis, or reduced kidney function at 6 months.  This trial has been 
criticized, because the sample size was small; also, there was no biopsy confirmation of cast 
nephropathy. More recently, high-cutoff hemodialysis has emerged as a means of extracorporeal 
removal of free light chains as an adjuvant to chemotherapy in the treatment of cast nephropathy. 
Prolonged dialysis (6- to 8-hour sessions) is performed with a hemodialyzer with a large pore size (45–60 
kD). In vitro studies showed that high-cutoff hemodialysis could achieve removal of 90% of free light 
chains over a 3-week period (6). Retrospective studies using high-cutoff hemodialysis showed significant 
reductions in free light-chain concentrations and improved kidney function. In patients with biopsy-
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confirmed severe cast nephropathy treated with and extracorporeal therapy (high-cutoff hemodialysis 
or plasmapheresis) and either bortezomib or thalidomide, a 60% reduction in serum free light-chain 
concentrations within 21 days was associated with kidney recovery in 80% of patients; in patients 
receiving dialysis, 63% became dialysis independent. In the largest study of 67 patients on dialysis 
treated with high-cutoff hemodialysis, 63% of patients became dialysis independent (7). However, this 
and all previous trials were conducted during the era of bortezomib based chemotherapy, and they 
lacked randomization and control patients. To address this inadequacy, two randomized, controlled 
trials using high-cutoff hemodialysis have now been completed. 
In the Multiple Myeloma and Renal Failure due to Myeloma Cast Nephropathy (MYRE) Trial, a total of 98 
patients with biopsy-confirmed cast nephropathy requiring dialysis were randomized to either intensive 
high-flux hemodialysis or high-cutoff hemodialysis (eight sessions of 5 hours in duration over the first 
10 days and then thrice weekly in both groups) (8). Patients initially entered a screening period that 
involved administration of high-dose steroids; correction of volume depletion and other precipitating 
factors, such as hypercalcemia; and kidney biopsy. Patients with cast nephropathy who required dialysis 
were subsequently randomized after the screening period. All patients received bortezomib-based 
chemotherapy. There was no significant difference in the primary end point of dialysis independence at 
3 months between the control and high-cutoff hemodialysis groups (33% versus 43%, respectively; 
P50.42), although the median reduction rate of free light chains after the first dialysis session was 
significantly higher in the high-cutoff hemodialysis group (68%) compared with the control group (31%; 
P50.001). The rate of kidney recovery in the control group was similar to that reported in retrospective 
studies in patients treated with bortezomib-based chemotherapy regimens alone (30%–50%). In 
secondary analyses, significantly more patients in the high-cutoff hemodialysis group were dialysis 
independent at 6 months (56.5% versus 35.4%; P50.04) as well as 12 months (60.9% versus 37.5%; 
P50.02). Dialysis independence at 12 months was associated with a decrease in serum free light-chain 
concentration to ,500 mg/L with the first round of chemotherapy (P50.01) and randomization to high-
cutoff hemodialysis (P50.02). Overall, this study may have been underpowered to show a small but 
clinically significant benefit on the primary outcome because of the small number of patients 
The European Trial of Free Light Chain Removal by Extended Hemodialysis in Cast Nephropathy (EuLITE) 
similarly randomized 90 patients with biopsy-proven cast nephropathy requiring dialysis to either 
conventional high-flux hemodialysis on the basis of clinical grounds (a minimum of 4-hour sessions 
thrice weekly) or extended high-cutoff hemodialysis (8-hour sessions on 8 of the first 10 days and then 
on alternate days) (C.C.P. Hutchison et al., unpublished data). All patients received bortezomib-based 
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chemotherapy. There was no difference in the primary end point of dialysis independence at 3 months 
between the control (51.6%) and intervention (55.8%) groups (relative risk, 1.07; 95% confidence 
interval, 0.73 to 1.59). Although there were large early reductions in serum free light-chain 
concentrations from pretreatment levels at days 4–6, there were no significant differences in median 
reduction rate of free light chains. There was a significant increase in the risk of pulmonary infections in 
the first 3 months in patients receiving high-cutoff hemodialysis (relative risk, 1.79; 95% confidence 
interval, 1.2 to 2.4; P,0.01). The rates of dialysis independence at 6 and 12 months were not reported.  
This study may have been underpowered to show a small but clinically significant benefit on the primary 
outcome because of the small number of patients. Because the EuLITE has only been published in 
abstract form, these findings should be interpreted cautiously until released in peer-reviewed fashion. 
It should be noted that there were several differences in the conduct of these two trials. The protocols 
differed in predialysis care, initial chemotherapeutic regimens, intensity of dialysis, and type of dialyzers 
used. 
Despite the successful completion of these two trials, the role of high-cutoff hemodialysis in the 
treatment of cast nephropathy is still unsettled. Both studies failed to show an effect on the primary end 
point of dialysis independence at 3 months but may have bene underpowered to detect small but 
clinically significant benefit. Prolonged high-cutoff hemodialysis is not without risk. It is associated with a 
need for regular phosphate and albumin supplementation (the MYRE Trial) as well as a potential 
increase in infection risk (the EuLITE). Therefore, high-cutoff hemodialysis must still be considered an 
unproven adjunct therapy until more robust clinical data are reported, and it is likely unwarranted in 
non-dialysis-dependent AKI. Given the variable cytogenetics, type of free light chains, time course, and 
different medical treatment protocols associated with multiple myeloma, well designed trials of high-
cutoff hemodialysis are still warranted in the future. 
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